HC Wainwright Reaffirms Buy Rating for Blueprint Medicines (NASDAQ:BPMC)
HC Wainwright reiterated their buy rating on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a report released on Monday, Benzinga reports. HC Wainwright currently has a $85.00 price target on the biotechnology company’s stock. A number of other equities research analysts have also issued reports on BPMC. Barclays upped their target price on […]
More Stories
Banque Cantonale Vaudoise Buys 8,171 Shares of Public Service Enterprise Group Incorporated (NYSE:PEG)
Banque Cantonale Vaudoise boosted its stake in shares of Public Service Enterprise Group Incorporated (NYSE:PEG – Free Report) by 11.2%...
Aberdeen Wealth Management LLC Has $212,000 Holdings in iShares Silver Trust (NYSEARCA:SLV)
Aberdeen Wealth Management LLC cut its holdings in shares of iShares Silver Trust (NYSEARCA:SLV – Free Report) by 40.1% in...
Amara Financial LLC. Buys New Shares in iShares Core MSCI EAFE ETF (BATS:IEFA)
Amara Financial LLC. bought a new position in iShares Core MSCI EAFE ETF (BATS:IEFA – Free Report) during the third...
Verity & Verity LLC Increases Position in Medtronic plc (NYSE:MDT)
Verity & Verity LLC raised its stake in shares of Medtronic plc (NYSE:MDT – Free Report) by 3.7% during the...
Whalen Wealth Management Inc. Has $350,000 Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)
Whalen Wealth Management Inc. reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 6.5% during the 3rd...
Verity & Verity LLC Sells 26,959 Shares of QUALCOMM Incorporated (NASDAQ:QCOM)
Verity & Verity LLC trimmed its holdings in shares of QUALCOMM Incorporated (NASDAQ:QCOM – Free Report) by 33.6% in the...